BioLargo, Inc.
BLGO
$0.16
$0.00-1.82%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -56.33% | -41.57% | -16.42% | 22.97% | 45.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -56.33% | -41.57% | -16.42% | 22.97% | 45.40% |
| Cost of Revenue | -56.11% | -43.94% | -13.88% | 38.05% | 63.33% |
| Gross Profit | -56.60% | -38.59% | -19.29% | 7.73% | 27.68% |
| SG&A Expenses | 68.21% | 64.32% | 8.19% | 12.62% | 15.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.24% | 6.63% | -0.88% | 22.49% | 34.60% |
| Operating Income | -242.75% | -274.74% | -68.64% | -21.07% | -3.14% |
| Income Before Tax | -249.41% | -251.55% | -61.52% | -11.44% | 6.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -249.41% | -251.55% | -61.52% | -11.44% | 6.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 75.32% | 93.61% | 106.98% | 85.90% | 70.02% |
| Net Income | -390.38% | -364.81% | -40.22% | 14.18% | 31.45% |
| EBIT | -242.75% | -274.74% | -68.64% | -21.07% | -3.14% |
| EBITDA | -252.00% | -284.50% | -70.11% | -19.31% | -1.95% |
| EPS Basic | -370.37% | -345.83% | -34.38% | 17.97% | 34.15% |
| Normalized Basic EPS | -600.00% | -763.16% | -30.56% | 29.63% | 46.15% |
| EPS Diluted | -370.37% | -345.83% | -34.38% | 17.97% | 34.15% |
| Normalized Diluted EPS | -600.00% | -763.16% | -30.56% | 29.63% | 46.15% |
| Average Basic Shares Outstanding | 2.96% | 2.82% | 3.19% | 3.64% | 4.26% |
| Average Diluted Shares Outstanding | 2.96% | 2.82% | 3.19% | 3.64% | 4.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |